drugset
drugset / Trial / NCT04620759

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

NCT04620759 ↗

Phase 2 Active not recruiting 90 enrolled Johns Hopkins University Usona Institute · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether psilocybin, a hallucinogenic drug, is effective in reducing depressive symptoms and amount of drinking in patients with co-occurring Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD).

Timeline

Start
2021-04-14
Primary completion
2026-03-02
Completion
2027-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 25 mg Oral

Indications

alcohol-related disorders major depressive disorder